Trials / Conditions / Transarterial Chemoembolization

Transarterial Chemoembolization

20 registered clinical trials studyying Transarterial Chemoembolization — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Adjuvant TACE in HCC With High-risk Recurrence Factors NCT07417397	Guangxi Medical University	Phase 3
Not Yet Recruiting	Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unrese NCT07281664	Third Affiliated Hospital, Sun Yat-Sen University	N/A
Recruiting	qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver NCT06971991	University of Wisconsin, Madison	N/A
Recruiting	Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesion NCT07198230	Ting YANG	—
Recruiting	TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma NCT06485466	Guohui Xu	Phase 3
Completed	Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transart NCT07315022	First Affiliated Hospital, Sun Yat-Sen University	Phase 4
Completed	DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma NCT04834674	Sichuan Cancer Hospital and Research Institute	Phase 2
Recruiting	Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Ca NCT06788353	Sun Yat-sen University	—
Recruiting	Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization NCT07178093	Taichung Tzu Chi Hospital	N/A
Unknown	Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma NCT05416073	The Second Affiliated Hospital of Chongqing Medical University	Phase 4
Unknown	cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC NCT05025592	Peking University Cancer Hospital & Institute	—
Unknown	Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolizati NCT05390112	University Hospital, Rouen	—
Unknown	TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC NCT04597970	Peking University Cancer Hospital & Institute	Phase 2
Unknown	TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial NCT04531228	Yunfei Yuan	N/A
Completed	The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein NCT04997850	Xinrui Zhu，MD	Phase 1 / Phase 2
Completed	TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma NCT04103398	Sun Yat-sen University	Phase 3
Completed	CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC NCT07449065	First Affiliated Hospital, Sun Yat-Sen University	—
Unknown	Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge NCT03277716	Fan Weijun	N/A
Unknown	Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Car NCT01677468	Hallym University Medical Center	N/A
Completed	A New Conception About Individualized Treatment Allocation for HCC NCT06008548	Tang-Du Hospital	—